Related Experiment Video

Updated: May 13, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Dexmedetomidine: antiarrhythmic effects in the pediatric cardiac patient

Joseph D Tobias1, Constantinos Chrysostomou

  • 1Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Ohio State University, 700 Children's Drive, Columbus, OH 43205, USA. Joseph.Tobias@Nationwidechildrens.org

Pediatric Cardiology
|February 26, 2013
PubMed

Insights

Dexmedetomidine shows promise for treating and preventing tachyarrhythmias in pediatric patients. Evidence suggests cardiovascular benefits, particularly in managing arrhythmias during and after cardiac surgery.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Dexmedetomidine's cardiovascular effects are well-documented in adult and animal models.
  • Clinical experience in pediatrics is growing, highlighting its potential in managing arrhythmias.
  • The drug is widely used for sedation in children, though not FDA-approved for this population.

Purpose of the Study:

  • To review the cardiovascular effects of dexmedetomidine, focusing on conduction.
  • To provide an evidence-based assessment of dexmedetomidine for treating and preventing tachyarrhythmias in pediatric patients.

Main Methods:

  • Computerized bibliographic search of existing literature.
  • Review of studies on dexmedetomidine's use in treating and preventing arrhythmias in infants and children.

Main Results:

  • Dexmedetomidine demonstrates potential therapeutic applications in the acute treatment of pediatric arrhythmias.
  • Its use in cardiac surgery correlates with reduced incidence of postoperative tachyarrhythmias.
  • Studies indicate dexmedetomidine may be effective for acute treatment and prevention of tachyarrhythmias.

Conclusions:

  • Dexmedetomidine shows promise for the acute management and prevention of tachyarrhythmias in pediatric populations.
  • Further research may solidify its role in pediatric cardiac care, despite current FDA limitations.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...